SCHEMBL34467320

SCHEMBL34467320

COc1ccc(/C(C)=C/C(=O)O)cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 2/20 0.58
GPR183 P32249 2/20 0.53
MKNK1 Q9BUB5 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
MAPT P10636 2/20 0.45
NR4A1 P22736 1/20 0.45
NR4A2 P43354 1/20 0.45
NR4A3 Q92570 1/20 0.45
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
OXTR P30559 1/20 0.44
TBXAS1 P24557 2/20 0.43
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
KDM4E B2RXH2 2/20 0.40
KCNH2 Q12809 1/20 0.40
ALDH1A1 P00352 2/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1843116 0.88 MKNK1 (0.62) NNMTGPR183MKNK1MKNK2NR4A1
SCHEMBL34467450 0.86 NNMT (0.57) NNMTGPR183MKNK1MKNK2MAPT
SCHEMBL13719312 0.81 NNMT (0.55) NNMTGPR183MKNK1MKNK2MAPT
SCHEMBL6447997 0.81 NNMT (0.58) NNMTGPR183MKNK1MKNK2MAPT
SCHEMBL17273934 0.80 NR4A1 (0.47) NNMTGPR183NR4A1NR4A2NR4A3
SCHEMBL29757598 0.79 NNMT (0.70) NNMTMKNK1MKNK2MAPTOXTR
SCHEMBL185291 0.79 NNMT (0.70) NNMTMKNK1MKNK2MAPTOXTR
SCHEMBL105066 0.79 NNMT (0.70) NNMTGPR183MKNK1MKNK2MAPT
SCHEMBL29514668 0.79 NNMT (0.70) NNMTGPR183MKNK1MKNK2MAPT
SCHEMBL3034306 0.78 NNMT (0.54) NNMTGPR183MKNK1MKNK2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138977-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-12612396-B1 Modulators of beta catenin and uses thereof DEWPOINT THERAPEUTICS, INC. (US) 2026-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612396-B1 Modulators of beta catenin and uses thereof CTNNB1, CTNND1, CTNNA1 NNMT 3399/4885GPR183 3841/4885MKNK1 809/4885
US-20260138977-A1 MODULATORS OF BETA CATENIN AND USES THEREOF CTNNB1, CTNND1, CTNNA1 NNMT 3399/4885GPR183 3841/4885MKNK1 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.